Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone Capsule in Advanced Ovarian Cancer
NCT07044349Phase 2Not yet recruiting
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Mar 2027
- Modality
- Allosteric Modulators
01
Overview
A Phase 2 trial of utidelone in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Beijing Biostar Pharmaceuticals Co., Ltd.. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
utidelone
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07044349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07044349.